N-Ethyltryptamine (NET), also abbreviated as NETP, is a tryptamine that is structurally related to N-methyltryptamine (NMT) and the psychedelic drugs N,N-dimethyltryptamine (DMT) and N,N-diethyltryptamine (DET).
Alexander Shulgin included NET as an entry in his book TiHKAL (Tryptamines I Have Known and Loved). However, he stated that it had been subjected only to modest human trials and that no active dose level had been identified.
NET has been found to act as a potent serotonin 5-HT<sub>2A</sub> receptor full agonist and a selective serotonin releasing agent. It is inactive at the 5-HT<sub>1A</sub> receptor.
The chemical synthesis of NET has been described.
Analogues of NET include N-methyltryptamine (NMT), dimethyltryptamine (DMT), methylethyltryptamine (MET), and diethyltryptamine (DET), among others.
NET is not a controlled substance in Canada as of 2025.